KMYY(SH:600518)2024-07-12 09:07Financial Performance Expectations - The company expects a net profit attributable to shareholders of the parent company for the first half of 2024 to be between 14 million and 21 million yuan, marking a turnaround from a loss in the same period last year [2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between -120 million and -90 million yuan [2]. - In the same period last year, the total profit was -115.47 million yuan, and the net profit attributable to shareholders was -125.86 million yuan [4]. Revenue and Profit Growth - The Chinese medicine segment is expected to see revenue growth of over 20% year-on-year, with gross profit increasing by approximately 55 million yuan [5]. - The company anticipates a reduction in related expenses by approximately 5 million yuan through refined expense management [5]. - Non-operating gains include an estimated 28 million yuan from the disposal of non-current assets and 50 million yuan from debt resolution efforts [5]. - The company expects a reversal of credit impairment losses amounting to approximately 42 million yuan through various debt collection strategies [5]. Performance Forecast and Risks - The performance forecast has not been audited by a registered accountant, and the data is preliminary [6]. - There are no significant uncertainties affecting the accuracy of the performance forecast [6]. - Investors are advised to pay attention to investment risks as the final financial data will be disclosed in the official half-year report [6].